237 related articles for article (PubMed ID: 25772947)
21. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
Dave V; Chiang CY; Booth J; Mount PF
Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
[TBL] [Abstract][Full Text] [Related]
22. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T
Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381
[TBL] [Abstract][Full Text] [Related]
23. [Hypocalcemia with encephalopathy and epileptic seizures secondary to treatment with denosumab].
Rodríguez-Gómez D; Lustres-Pérez M; Rodríguez-Noguera MV; Pérez-Carral V; Fernández-Regal I
Rev Neurol; 2015 Feb; 60(4):189-90. PubMed ID: 25670049
[No Abstract] [Full Text] [Related]
24. Extreme hypocalcaemia and hyperparathyroidism following denosumab. Is this drug safe in chronic kidney disease?
Sirvent AE; Enríquez R; Sánchez M; González C; Millán I; Amorós F
Nefrologia; 2014; 34(4):542-4. PubMed ID: 25036077
[No Abstract] [Full Text] [Related]
25. Denosumab-induced severe hypocalcemia in a patient with Paget's disease of bone and impaired renal function.
Kostine M; Mehsen-Cetre N; Bannwarth B
Therapie; 2017 Jun; 72(3):383-385. PubMed ID: 27745697
[No Abstract] [Full Text] [Related]
26. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
Park SY; Kim J; Chung HY
Osteoporos Int; 2022 Jan; 33(1):305-308. PubMed ID: 34232341
[TBL] [Abstract][Full Text] [Related]
27. Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report.
Quiroga García V; Cirauqui Cirauqui B; Tobey Robaina L; López Sisamon D; Hardy-Werbin M; Blanca AB; Margelí Vila M
Anticancer Drugs; 2016 Jun; 27(5):464-9. PubMed ID: 26813866
[TBL] [Abstract][Full Text] [Related]
28. Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: a multicenter, retrospective, observational study.
Nakamura K; Kaya M; Yanagisawa Y; Yamamoto K; Takayashiki N; Ukita H; Nagura M; Sugiue K; Kitajima M; Hirano K; Ishida H; Onoda C; Kobayashi Y; Nakatani E; Odagiri K; Suzuki T
BMC Cancer; 2024 Feb; 24(1):218. PubMed ID: 38360579
[TBL] [Abstract][Full Text] [Related]
29. Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis.
Ota S; Inoue R; Shiozaki T; Yamamoto Y; Hashimoto N; Takeda O; Yoshikawa K; Ito J; Ishibashi Y
Breast Cancer; 2017 Jul; 24(4):601-607. PubMed ID: 27943163
[TBL] [Abstract][Full Text] [Related]
30. Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D
Ikegami K; Hashiguchi M; Kizaki H; Yasumuro O; Funakoshi R; Hori S
J Clin Pharmacol; 2022 Sep; 62(9):1151-1159. PubMed ID: 35383950
[TBL] [Abstract][Full Text] [Related]
31. Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
Cömlekçi A; Biberoglu S; Hekimsoy Z; Okan I; Pişkin O; Sekeroglu B; Alakavuklar M
Intern Med; 1998 Apr; 37(4):396-7. PubMed ID: 9630201
[TBL] [Abstract][Full Text] [Related]
32. Life-threatening hypocalcaemia associated with denosumab in advanced chronic kidney disease.
Killen JP; Yong K; Luxton G; Endre Z
Intern Med J; 2016 Jun; 46(6):746-7. PubMed ID: 27257154
[No Abstract] [Full Text] [Related]
33. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.
Yasuda Y; Iwama S; Arima H
Endocr J; 2019 Mar; 66(3):271-275. PubMed ID: 30713246
[TBL] [Abstract][Full Text] [Related]
34. High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.
Ishikawa K; Nagai T; Tsuchiya K; Oshita Y; Kuroda T; Ito H; Tani S; Dodo Y; Toyone T; Inagaki K
Clin Interv Aging; 2018; 13():1929-1934. PubMed ID: 30349211
[TBL] [Abstract][Full Text] [Related]
35. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.
Watkins KR; Rogers JE; Atkinson B
Support Care Cancer; 2015 Jun; 23(6):1657-62. PubMed ID: 25421444
[TBL] [Abstract][Full Text] [Related]
36. Denosumab anf cronic kidney disease: Severe life-threatening hypocalcemia.
Monge Rafael P; Martin de Francisco ÁL; Fernández-Fresnedo G
Nefrologia (Engl Ed); 2018; 38(1):97-98. PubMed ID: 29325673
[No Abstract] [Full Text] [Related]
37. Symptomatic hypocalcemia following a single dose of zoledronic acid in a patient with bone metastases secondary to breast cancer.
Sözel H; Yilmaz F
J Oncol Pharm Pract; 2021 Mar; 27(2):494-497. PubMed ID: 32660376
[TBL] [Abstract][Full Text] [Related]
38. Multiple Factors in Recurrent Symptomatic Hypocalcemia Following Denosumab in a Patient Receiving Home Parenteral Nutrition.
Chandurkar V; Marliss EB
JPEN J Parenter Enteral Nutr; 2016 Jul; 40(5):734-8. PubMed ID: 25681492
[No Abstract] [Full Text] [Related]
39. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
[TBL] [Abstract][Full Text] [Related]
40. Severe hypocalcaemia following denosumab in a patient with cancer with vitamin D deficiency.
Watthanasuntorn K; Abid H; Gnanajothy R
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
